These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12062743)

  • 1. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study).
    Tamberella MR; Bhatt DL; Chew DP; Kereiakes DJ; Topol EJ; Steinhubl SR;
    Am J Cardiol; 2002 Jun; 89(12):1429-31. PubMed ID: 12062743
    [No Abstract]   [Full Text] [Related]  

  • 2. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
    Steinhubl SR; Talley JD; Braden GA; Tcheng JE; Casterella PJ; Moliterno DJ; Navetta FI; Berger PB; Popma JJ; Dangas G; Gallo R; Sane DC; Saucedo JF; Jia G; Lincoff AM; Theroux P; Holmes DR; Teirstein PS; Kereiakes DJ
    Circulation; 2001 May; 103(21):2572-8. PubMed ID: 11382726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
    Simpfendorfer C; Kottke-Marchant K; Lowrie M; Anders RJ; Burns DM; Miller DP; Cove CS; DeFranco AC; Ellis SG; Moliterno DJ; Raymond RE; Sutton JM; Topol EJ
    Circulation; 1997 Jul; 96(1):76-81. PubMed ID: 9236420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease.
    Lefkovits J; Topol EJ
    Eur Heart J; 1996 Jan; 17(1):9-18. PubMed ID: 8682137
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 11. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
    JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 14. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resisting the temptation to oversimplify antiplatelet resistance.
    Bhatt DL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):660-2. PubMed ID: 19463381
    [No Abstract]   [Full Text] [Related]  

  • 18. [Monitoring of tienopyridines or glycoprotein IIb/IIIa-receptor antagonists: simple platelet function tests].
    Halbmayer WM
    Hamostaseologie; 2004 Aug; 24(3):203-6. PubMed ID: 15314706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention in octogenarians and the safety of glycoprotein IIb/IIIa inhibitors.
    Ragosta M
    J Am Coll Cardiol; 2003 Aug; 42(3):433-6. PubMed ID: 12906968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.